Skip to Content

LCE 125 (Carbidopa, entacapone and levodopa 31.25 mg / 200 mg / 125 mg)

Pill imprint LCE 125 has been identified as Carbidopa, entacapone and levodopa 31.25 mg / 200 mg / 125 mg.

Carbidopa/entacapone/levodopa is used in the treatment of parkinson's disease and belongs to the drug class dopaminergic antiparkinsonism agents. Risk cannot be ruled out during pregnancy. Carbidopa/entacapone/levodopa 31.25 mg / 200 mg / 125 mg is not a controlled substance under the Controlled Substance Act (CSA).

Carbidopa, entacapone and levodopa 31.25 mg / 200 mg / 125 mg LCE 125  Front
Carbidopa, entacapone and levodopa 31.25 mg / 200 mg / 125 mg LCE 125  Back
Carbidopa, entacapone and levodopa 31.25 mg / 200 mg / 125 mg LCE 125
Discount Card Promo
Carbidopa, entacapone and levodopa
Imprint:
LCE 125
Strength:
31.25 mg / 200 mg / 125 mg
Color:
Red
Shape:
Elliptical / Oval
Availability:
Prescription only
Drug Class:
Dopaminergic antiparkinsonism agents
Pregnancy Category:
C - Risk cannot be ruled out
CSA Schedule:
Not a controlled drug
Manufacturer:
Sandoz Inc

More info Print Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.

Hide